Investor Quick Links
Aspira is led by an experienced team of business, medical and scientific professionals with a passion for improving health outcomes for women.
About Aspira Women's Health
Our Mission
Aspira Women's Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products Ova1® and Overa® detect the risk of ovarian malignancy in women with adnexal masses. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.
Most Recent Press Releases
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President
March 18, 2024 08:00 ET Dr. Milligan brings a wealth of experience across critical business functions and deep relationships with leaders throughout the healthcare and pharmaceutical sectors Aspira also announces Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team following the departure of Dr. Jody Berry AUSTIN, Texas, March…
Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
March 11, 2024 08:00 ET AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended…